الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Chronic liver diseasesare considered as a crucial public health problem world wide leading tosignificant increase inmorbidity and mortality ratesover the years.Globally, CLD sresulted inalmost 2 million deaths eachyear.
Moreover, CLDs bring about higheconomic burdenandpoor quality of life in affected individuals. In regard to that, liver fibrosis is considered as a frequent and potentially life-threatening complication associated with most CLDs. The introductory part of the thesis highlightedthe prevalence of liver diseases worldwide and particularly in Egypt. It also provided background information on pathophysiology, etiology, diagnosisand different treatment targets of liver fibrosis.The importance of nanotechnology in the management of liver fibrosis wasalso highlighted.Furthermore, an overview of the drugs used in the management of liver fibrosiswere listed. Among these a promising phytomedicinewith a well-documented efficacy against liver diseases and in particular liver fibrosis was TSIIA.
It is suffering from many obstacles like poor solubility, permeability, poor stability in elevated temperatures and first pass metabolism which limits both itsbioavailabilityand efficacy. Different approaches wereadopted to overcome the previous limitations of TSIIA therapy, such as the use of nanocarriersto improve its bioavailability and activity focusing on lipid-based systems investigated to date for the delivery of TSIIA.
These include mainly liposomes, solid lipid nanoparticles as well as micro andnanoemulsions. The thesis research hypothesis was to develop a new lipid based TSIIA delivery system aiming at enhancing its efficacy.
This could be achieved by a sufficiently high drug loading, adequate drug concentration reaching the target organ and stability of the developedcarrier in serum and gastrointestinal fluids. Lipid nanocapsules with favorable structural and biopharmaceutical characteristics were selected as a nanocarrier with great promises for effective parenteral and oral TSIIA delivery. Accordingly, the thesis objective was to develop TSIIA lipid nanocapsules as a potentiallynoveleffective hepatic antifibrotic nanomedicinal formulation.